2-amino-5-phosphonovalerate has been researched along with levodopa in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (77.78) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Arnold, G; Klockgether, T; Kupsch, A; Oertel, W; Renner, P; Scheid, C; Scheid, R; Wüllner, U | 1 |
| Chub, NL | 1 |
| Labruyere, J; Olney, JW; Price, MT; Stewart, GR; Wang, GJ; Zorumski, CF | 1 |
| Archer, T; Fredriksson, A; Gentsch, C | 1 |
| Maj, J; Rogóz, Z; Skuza, G | 1 |
| Goshima, Y; Kawashima, K; Misu, Y; Miyamae, T; Ohshima, E; Shibata, T; Shimizu, M; Suzuki, F | 1 |
| Archer, T; Chase, T; Fredriksson, A; Palomo, T | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M | 1 |
9 other study(ies) available for 2-amino-5-phosphonovalerate and levodopa
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
The competitive NMDA antagonist CGP40.116 enhances L-dopa response in MPTP-treated marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2-Amino-5-phosphonovalerate; Animals; Callithrix; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Motor Activity; N-Methylaspartate | 1992 |
[The action of L-DOPA on the spontaneous activity generated by the isolated spinal cord of 16- to 20-day-old chick embryos].
Topics: 2-Amino-5-phosphonovalerate; Animals; Chick Embryo; Dopamine; Dose-Response Relationship, Drug; In Vitro Techniques; Levodopa; Membrane Potentials; Norepinephrine; Perfusion; Periodicity; Spinal Cord; Spinal Nerve Roots; Time Factors | 1991 |
Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Chick Embryo; Dibenzocycloheptenes; Dihydroxyphenylalanine; Dizocilpine Maleate; Hippocampus; Huntington Disease; Levodopa; Neurons; Parkinson Disease; Quinoxalines; Receptors, Neurotransmitter; Retina | 1990 |
Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2-Amino-5-phosphonovalerate; Animals; Behavior, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; N-Methylaspartate; Receptors, N-Methyl-D-Aspartate; Stereoisomerism | 1994 |
Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity.
Topics: 2-Amino-5-phosphonovalerate; alpha-Methyltyrosine; Animals; Antiparkinson Agents; Antipsychotic Agents; Biogenic Monoamines; Catalepsy; Central Nervous System Agents; Clonidine; Levodopa; Male; Methyltyrosines; Motor Activity; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Reserpine; Tyrosine 3-Monooxygenase | 1993 |
Some interactions of L-DOPA and its related compounds with glutamate receptors.
Topics: 2-Amino-5-phosphonovalerate; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Dizocilpine Maleate; Dose-Response Relationship, Drug; Female; Kainic Acid; Levodopa; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Xenopus laevis | 1999 |
Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2-Amino-5-phosphonovalerate; Animals; Antiparkinson Agents; Differential Threshold; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Tolerance; Excitatory Amino Acid Antagonists; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; N-Methylaspartate; Sexual Behavior, Animal | 1999 |
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes | 2013 |